$-0.03
(Market cap
$456 Mln
Recently Viewed
Clear AllMarket cap
$456 Mln
Revenue (TTM)
$73 Mln
P/E Ratio
--
P/B Ratio
5.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-3.9
Debt to Equity
1.6
Book Value
$0.8
EPS
$-0.7
Face value
--
Shares outstanding
72,590,994
CFO
$-463.76 Mln
EBITDA
$-712.87 Mln
Net Profit
$-713.70 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| -18.4 | 18.3 | -9.6 | 174.3 | 27.6 | -27.1 | -18.0 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
| 168.9 | -41.3 | 46.7 | -74.1 | -70.0 | 58.1 | 2.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cellectis S.A. - ADR
|
4.0 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 |
| 19.5 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 28.9 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 14.0 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 8.7 | 399.7 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 16.8 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 3.9 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 7.9 | 355.7 | 0.6 | -88.6 | -15,110.2 | -90.3 | -- | 5.7 | |
| 5.5 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 | |
| 21.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates... in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Read more
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
Co-Founder, CEO & Director
Dr. Andre Choulika Ph.D.
Headquarters
Paris
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cellectis SA - ADR is $3.95 (NASDAQ) as of 23-Apr-2026 11:10 EDT. Cellectis SA - ADR has given a return of 27.63% in the last 3 years.
Since, TTM earnings of Cellectis SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.14
|
6.38
|
|
2024
|
-4.46
|
1.25
|
|
2023
|
-1.74
|
2.07
|
|
2022
|
-0.98
|
0.82
|
|
2021
|
-4.24
|
1.65
|
The 52-week high and low of Cellectis SA - ADR are Rs 5.48 and Rs 1.33 as of 23-Apr-2026.
Cellectis SA - ADR has a market capitalisation of $ 456 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cellectis SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.